Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Cardiol. Sep 26, 2014; 6(9): 929-938
Published online Sep 26, 2014. doi: 10.4330/wjc.v6.i9.929
Published online Sep 26, 2014. doi: 10.4330/wjc.v6.i9.929
Drug-eluting stents and acute myocardial infarction: A lethal combination or friends?
Shuji Otsuki, Manel Sabaté, Thorax Institute, Department of Cardiology, Hospital Clinic, University of Barcelona, 08015 Barcelona, Spain
Author contributions: All authors contributed to this work.
Correspondence to: Manel Sabaté, MD, PhD, Thorax Institute, Department of Cardiology, Hospital Clinic, University of Barcelona, C/Villaroel 170, 08036 Barcelona, Spain. masabate@clinic.ub.es
Telephone: +34-93-2275400 Fax: +34-93-2279305
Received: February 10, 2014
Revised: March 12, 2014
Accepted: July 17, 2014
Published online: September 26, 2014
Processing time: 229 Days and 11 Hours
Revised: March 12, 2014
Accepted: July 17, 2014
Published online: September 26, 2014
Processing time: 229 Days and 11 Hours
Core Tip
Core tip: Primary percutaneous coronary intervention is the preferred reperfusion strategy for patients presenting with ST-segment elevation myocardial infarction (STEMI). First-generation drug-eluting stents (DES) reduce restenosis and target vessel revascularization compared to bare metal stents at the expense of an increased stent thrombosis rate. Recent improvements in second-generation DES have overcome these safety concerns. This article presents an overview of safety and efficacy of the DES in STEMI.